Razoxane: a review of 6 years' therapy in psoriasisHORTON, J. J; WELLS, R. S.British journal of dermatology (1951). 1983, Vol 109, Num 6, pp 669-673, issn 0007-0963Article

BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDSHERMAN EH; WITIAK DT; HELLMANN K et al.1982; ADV. PHARMACOL. CHEMOTHER.; ISSN 0065-3144; USA; DA. 1982; VOL. 19; PP. 249-290; BIBL. 5 P.Article

BIS-DIKETOPIPERAZINE DERIVATIVES IN CLINICAL ONCOLOGY: ICRF-159POSTER DS; PENTA J; MARSONI S et al.1980; CANCER CLIN. TRIALS; ISSN 0190-1206; USA; DA. 1980; VOL. 3; NO 4; PP. 315-320; BIBL. 35 REF.Article

UTILIZATION OF AN ENANTIOMER AS A SOLUTION TO A PHARMACEUTICAL PROBLEM: APPLICATION TO SOLUBILIZATION OF 1,2-DI(4-PIPERAZINE-2,6-DIONE) PROPANEREPTA AJ; BALTEZOR MJ; BANSAL PC et al.1976; J. PHARM. SCI.; U.S.A.; DA. 1976; VOL. 65; NO 2; PP. 238-242; BIBL. 30 REF.Article

Razoxane and vindesine in advanced soft tissue sarcomas : Impact on metastasis, survival and radiation responseRHOMBERG, Walter; EITER, Helmut; SCHMID, Franz et al.Anticancer research. 2007, Vol 27, Num 5B, pp 3609-3614, issn 0250-7005, 6 p.Article

RAZOXANE REGIMEN FOR THE TREATMENT OF PSORIASISHARPER JI; COPEMAN PWM; STAUGHTON RCD et al.1982; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1982; VOL. 7; NO 2; PP. 217-218; BIBL. 1 REF.Article

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxaneANDERSON, H; YAP, J. T; WELLS, P et al.British journal of cancer. 2003, Vol 89, Num 2, pp 262-267, issn 0007-0920, 6 p.Article

TREATMENT OF KAPOSI'S SARCOMA WITH ICRF-159 (NSC-129943)OLWENY CLM; MASABA JP; SIKYEWUNDA W et al.1976; CANCER TREATM. REP.; U.S.A.; DA. 1976; VOL. 60; NO 1; PP. 111-113; BIBL. 7 REF.Article

REDUCTION OF DAUNOMYCIN TOXICITY BY RAZOXANEWANG G; FINCH MD; TREVAN D et al.1981; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1981; VOL. 43; NO 6; PP. 871-877; BIBL. 5 REF.Article

RANDOMIZED CLINICAL TRIAL COMPARING TWO DOSE REGIMENS OF ICRF-159 IN REFRACTORY MALIGNANT LYMPHOMASO'CONNELL MJ; BEGG CB; SILVERSTEIN MN et al.1980; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1980; VOL. 64; NO 12; PP. 1355-1358; BIBL. 4 REF.Article

RAZOXANEATHERTON DJ.1981; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1981; VOL. 6; NO 6; PP. 647-650; BIBL. 12 REF.Article

RAZOXANE (ICRF 159) IN THE TREATMENT OF PSORIASISATHERTON DJ; WELLS RS; LAURENT MR et al.1980; BRIT. J. DERMATOL.; GBR; DA. 1980; VOL. 102; NO 3; PP. 307-317; BIBL. 16 REF.Article

HYPOXIC CELL RADIOSENSITIZERS AND LOCAL CONTROL BY X-RAY OF A TRANSPLANTED TUMOUR IN MICE.SHELDON PW; HILL SA.1977; BRIT. J. CANCER; G.B.; DA. 1977; VOL. 35; NO 6; PP. 795-808; BIBL. 1 P. 1/2Article

TREATMENT OF BLAST CELL CRISIS OF CHRONIC MYELOID LEUKEMIA WITH ICRF-159 (RAZOXANE)BAKOWSKI MT; BREARLEY RL; WRIGLEY PFM et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 11-12; PP. 2085-2087; BIBL. 6 REF.Article

METAL BINDING BY PHARMACEUTICALS. II: INTERACTIONS OF CA(II), CU(II), FE(II), MG(II), MN(II) AND ZN(II) WITH THE INTRACELLULAR HYDROLYSIS PRODUCTS OF THE ANTITUMOUR AGENT ICRF 159 AND ITS INACTIVE HOMOLOGUE ICRF 192ZHONG XIAN HUANG; MAY PM; QUINLAN KM et al.1982; AGENTS AND ACTIONS; ISSN 0538-4818; CHE; DA. 1982; VOL. 12; NO 4; PP. 536-542; BIBL. 32 REF.Article

RAZOXANE REGIMEN FOR THE TREATMENT OF PSORIASISHARPER JI; COPEMAN PWM; STAUGHTON RCD et al.1982; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1982; VOL. 7; NO 5; PP. 581-582; BIBL. 1 REF.Article

A CONTROLLED PROSPECTIVE TRIAL OF ADJUVANT RAZOXANE IN RESPECTABLE COLORECTAL CANCERGILBERT JM; CASSELL PC; ELLIS H et al.1981; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1981; VOL. 79; PP. 48-58; BIBL. 15 REF.Conference Paper

RADIOTHERAPY AND ICRF 159 THE TREATMENT OF SOFT TISSUE SARCOMAS.RYALL RDH.1978; INTERACTION J. RAD. ONCOL. BIOL. PHYS.; U.S.A.; DA. 1978; VOL. 4; NO 1-2; PP. 133-134; BIBL. 6 REF.; (INTERACTION RADIAT. ANTITUMOR DRUGS. STANFORD CADE MEM. SYMP.; LONDON; 1976)Conference Paper

A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkińs lymphomaCORDER, M. P; MCFADDEN, D. B; BELL, S. J et al.Cancer. 1984, Vol 54, Num 8, pp 1496-1498, issn 0008-543XArticle

The mutagenic activity of razoxane (ICRF 159): an anticancer agentALBANESE, R; WATKINS, P. A.British journal of cancer. 1985, Vol 52, Num 5, pp 725-731, issn 0007-0920Article

A small prospective study of chordomas treated with radiotherapy and razoxaneRHOMBERG, Walter; BÖHLER, Franz-Karl; NOVAK, Hansjörg et al.Strahlentherapie und Onkologie. 2003, Vol 179, Num 4, pp 249-253, issn 0179-7158, 5 p.Article

Metal binding properties of two homologues of razoxane, a bisdioxopiperazine antitumour drugZHONG-XIAN HUANG; CREIGHTON, A. M; WILLIAMS, D. R et al.Inorganica chimica acta. 1985, Vol 107, Num 4, pp L29-L32, issn 0020-1693Article

Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung = Radiothérapie et razoxane dans les cancers moyennement avancés du poumonCORDER, M. P; TEWFIK, H. H; CLAMON, G. H et al.Cancer. 1984, Vol 53, Num 9, pp 1852-1856, issn 0008-543XArticle

Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas : Final results of a randomized studyRHOMBERG, W; HASSENSTEIN, E. O. M; GEFELLER, D et al.International journal of radiation oncology, biology, physics. 1996, Vol 36, Num 5, pp 1077-1084, issn 0360-3016Article

PHASE I TRIAL OF ICRF-187 BY 48-HOUR CONTINUOUS INFUSIONKOELLER JM; EARHART RH; DAVIS HL et al.1981; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1981; VOL. 65; NO 5-6; PP. 459-463; BIBL. 21 REF.Article